Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acne Pipeline Yields Three Disappointments, One Win So Far In 2017

Executive Summary

The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.


Related Content

Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants
Paratek Sees Broad Potential For Omadacycline After Second Phase III Win
Xenon Down On Novel Acne Treatment Failure
Valeant's Dermatology Sales Strategy: Teenage Zits
FDA's NDA And BLA Approvals
Allergan Bolsters Blockbuster Botox With Topical Toxin Buy
Valeant On Upswing With Walgreens Deal
Recently Listed Derma Firm Set for Phase III Acne Trial with NCE
Merry Christmas? Four US FDA approvals and a CRL


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts